Safety and Efficacy of Lorbrena

Pfizer

Status: Completed

Conditions: Non-small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT03844464

NCT03844464 (Registry Identifier)

B7461018

Details and patient eligibility

About

To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug

1. Factors affecting the onset of central nervous system disorder
2. Effect of Lorbrena in combination with CYP3A inducers on the onset of hepatic dysfunction

Enrollment: 1,290 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All administered patients

Exclusion criteria

• Nothing